Friday, January 04, 2013 5:19:25 AM
By shawnl
January 3, 2013
administrator
Scientists at Mount Sinai's Samuel Lunenfeld Research [http://www.lunenfeld.ca] Institute [http://www.lunenfeld.ca] have made a major discovery about the way that cancer spreads. In a study published in the journal Cell, Valbona Luga and Dr. Liang Zhang discovered that proteins produced in normal cells near the environment of a cancer tumour influences the cancer's ability to spread to other tissues of the body, a process called metastasis. The researchers work in the lab of Mount Sinai's Dr. Jeff Wrana, an international leader in cancer research.
One of the impacts of the study is the ability to target one of the proteins, called Cd81, to halt the spread of breast cancer and other cancers. The newly identified protein is part of tiny fragments of cells called exosomes. In a cancer state, the tumour cell releases exosomes to influence neighbouring cells. The researchers discovered that normal cells surrounding the tumour also secrete exosomes which help the tumour cells to spread.
"We wanted to find out how these different cells are communicating – from tumour cells to normal cells, and vice versa," says Dr. Jeff Wrana. "Classically, scientists have believed that communication between cells occurs in a simple fashion, that is, one signal (one word) back and forth. We found, to our disbelief, that these cells are exchanging whole paragraphs of information."
"Instead of only targeting the primary tumour, we can now pinpoint the cells in the tumour's environment that are responding to the tumour and target those too," says Valbona Luga. "We hope to use our new knowledge of the tumour's immediate surroundings to intercept its signals to cancer cells, and by doing so, drastically impede tumour spreading."
When exosomes were initially discovered in the 1980s, they were classified as little more than cell waste. In the 1990s, scientists linked their role to the healthy function of the immune system. Now, the Lunenfeld team has provided compelling evidence that exosomes are linked to cancer metastasis, and identified important proteins and molecules in normal cells and cancer cells that can be targeted to halt cancer's spread.
Funded by the Terry Fox Research Institute and CIHR (Canadian Institutes of Health Research), for this particular study Lunenfeld scientists also collaborated with Dr. Alicia Viloria-Petit from the Department of Biomedical Sciences at the University of Guelph and Dr. Mark Basik from the Lady Davis Institute for Medical Research at Jewish General Hospital in Montreal.
Recent AEMD News
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM